DexCom, Inc. (NASDAQ:DXCM) Files An 8-K Results of Operations and Financial Condition
RESULTS OF OPERATIONS AND FINANCIAL CONDITION.On February21, 2019, DexCom, Inc. (“DexCom”) issued a press release announcing its financial results for the quarter ended December31, 2018and certain other information.
This press release has been furnished as Exhibit 99.01 to this report and is incorporated herein by this reference.
. . . but first a Flashback!
_________________________________________________________________________
READERS OF THIS BLOG MIGHT REMEMBER SOME DOUBTS EXPRESSED IN THIS POST FROM JUNE 16, 2016
16 June 2016
Update > Dexcom Gambles On Move to Mesa Fiesta District > Volatile Stock Performance/Heavy Insider Trading
According to a report in Plastics Today on June 22, 2016 manufacturing operations in the 180,000-square-foot facility are expected to commence by the second quarter of 2017. . . Mesa Mayor John Giles told KJJZ.org that the city is offering to pay Dexcom $750 for each Mesa resident it hires. The incentive is capped at 300 hires, which would represent a total cost to the city of $225,000. The company projects creating more than 500 jobs over the next several years.
Dexcom (Nasdaq: DXCM), a San Diego-based continuous glucose monitoring manufacturer, is taking a 216,000-square-foot building on South Dobson Road near Loop 101 in Mesa’s Fiesta District.
Source: Phoenix Business Journal Eric Jay Toll
Likewise for reference are two over-the-top "good news" stories
READ MORE >> MesaZona 16 June 2016
_________________________________________________________________________
AZCentral.com-May 8, 2017
Mesa and Arizona leaders join Dexcom CEO Kevin Sayer at a ribbon-cutting event for the company's new Mesa facility on April 25, 2017. (Photo11: Dexcom).
Phoenix Business Journal-Apr 14, 2017
Dexcom Inc. (Nasdaq: DXCM), a San Diego-based manufacturer of ... where a select number of employers got a chance to see why Arizona would be a good ...
_________________________________________________________________________________
Back to the Market Exclusive press release:On February 20, 2019, DexCom’s Board of Directors committed DexCom to a restructuring plan that will result in the transition of certain of DexCom’s operations to the Philippines (the “Restructuring”). The Restructuring is designed to reduce operating expenses to improve cost competitiveness, enable strategic flexibility and increase the scalability of certain business functions.
DexCom expects the Restructuring to impact approximately 350 full time employees, or approximately 13% of DexCom’s total full time workforce as of December 31, 2018. The Restructuring also will impact DexCom’s employment or hiring of full-time temporary employees. Most of the affected employees currently work in DexCom’s facilities in San Diego, California and Mesa, Arizona.
DexCom currently estimates that it will incur pre-tax charges and costs of approximately $25 million, primarily related to severance, other one-time termination benefits, and related restructuring facilitation costs. Of these charges, DexCom expects a majority to be cash-based primarily related to severance and termination related benefits. These costs are primarily expected to be incurred throughout 2019 and DexCom expects to record the majority of the charges in the first half of 2019. DexCom expects the majority of the Restructuring activities to be completed by the end of 2019.
DEXCOM INC ExhibitEX-99.01 2 dxcmq4201899-1.htm EXHIBIT 99.01 Exhibit Exhibit 99.01Dexcom Reports Fourth Quarter and Fiscal Year 2018 Financial ResultsThe Company also Announces Expansion and Reorganization of its Customer Support FunctionsSAN DIEGO,…
To view the full exhibit click
here_______________________________________________________________
About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and a mobile application on the patient’s iPhone to transmit glucose information.
_______________________________________________________________
Forward-Looking Statements Disclaimer
The foregoing disclosures constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are preliminary estimates and expectations based on current information and are subject to business and economic risks and uncertainties that could cause actual events or actual future results to differ materially from the expectations set forth in the forward-looking statements. Important factors that could cause results to differ materially from the statements herein include: DexCom’s ability to implement the Restructuring as currently planned; possible changes in the size and timing of the Restructuring; the components and amount of the expected costs and charges associated with the Restructuring; the timing of the payment of the expected costs and charges; the timing of recording the expected charges and costs; and risks associated with DexCom’s ability to achieve the benefits of the Restructuring.You should refer to the section entitled “Risk Factors” set forth in DexCom’s annual and quarterly reports and other filings DexCom makes with the Securities and Exchange Commission from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by DexCom’s forward-looking statements. The forward-looking statements speak only as of the date of this Current Report. DexCom undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
